步长制药：关于全资子公司获得药品注册证书的公告

Group 1 - The core point of the article is that the company, Buchang Pharmaceutical, announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has received the drug registration certificate for Oseltamivir Phosphate Capsules from the National Medical Products Administration [2] Group 2 - The approval of the drug registration certificate indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio and market presence [2] - Oseltamivir is commonly used for the treatment of influenza, suggesting that the company is entering a competitive pharmaceutical market [2] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the antiviral medication segment [2]